Tioga Cardiovascular

Executive Summary

Tioga Cardiovascular is a private medical device company pioneering a novel transcatheter mitral valve replacement (TMVR) system for treating mitral regurgitation. Founded in 2018 and headquartered in San Diego, the company's Tioga TMVR System aims to address the limitations of current TMVR devices by offering a procedurally simpler approach designed to treat a broader patient population, including those with challenging anatomy. The system is in the early clinical stages, with the company likely conducting first-in-human or early feasibility studies. Mitral regurgitation is a large and growing market, and a successful TMVR solution could capture significant share. However, as a private company with limited public information, Tioga faces the typical risks of early-stage medtech: regulatory hurdles, clinical validation, and funding requirements. The company has not disclosed funding rounds or valuation, but its technology has the potential to be disruptive if clinical results are positive.

Upcoming Catalysts (preview)

• H2 2026Early Feasibility Study (EFS) Results70% success
• Q3 2026FDA IDE Approval for Pivotal Trial60% success
• Q4 2026Series B or C Financing Round75% success